Obsidian Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: (781) 806-6245
Website: https://obsidiantx.com/
Email: info@obsidiantx.com
About Obsidian Therapeutics
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients for the treatment of cancer and other diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
45 articles with Obsidian Therapeutics
-
Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022
11/7/2022
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its recent cytoDRiVE® platform and pipeline advances during the poster sessions at the upcoming SITC Annual Meeting 2022.
-
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
10/27/2022
Obsidian Therapeutics, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties' multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian's cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L.
-
FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
-
MD Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115
7/21/2022
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.
-
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022
5/17/2022
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022.
-
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022
4/11/2022
Obsidian Therapeutics, Inc. preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022.
-
Obsidian Therapeutics Appoints Maria Fardis, Ph.D., as Chair of its Board of Directors
1/19/2022
Obsidian Therapeutics, Inc. today announced that Maria Fardis , Ph.D., has assumed the role of Chair of Obsidian's Board of Directors.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
-
Precision Gene Therapy on the Cusp
1/11/2022
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences. -
BioSpace Movers & Shakers, Nov. 19
11/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Obsidian Therapeutics Appoints Heidi Hagen to Board of Directors
11/16/2021
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, announced the appointment of Heidi Hagen to its Board of Directors.
-
Obsidian Therapeutics to Present In Vivo Anti-Tumor Efficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021
11/9/2021
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
BioSpace Movers & Shakers, Oct. 22
10/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors
10/21/2021
Obsidian Therapeutics, Inc. today announced the appointment of Maria Fardis , Ph.D., to its Board of Directors.
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021
9/15/2021
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology Congress, which will be hosted virtually September 16-21, 2021.
-
Money on the Move: September 8 – 14
9/15/2021
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies. -
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
9/9/2021
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover Fund (TCGX).
-
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting
5/4/2021
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021.